155 research outputs found
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
No full textMantle cell lymphoma and other lymphoma subtypes often spread to the bone marrow, and stromal interactions mediated by focal adhesion kinase frequently enhance survival and drug resistance of the lymphoma cells. To study the role of focal adhesion kinase in mantle cell lymphoma, immunohistochemistry of primary cases and functional analysis of mantle cell lymphoma cell lines and primary mantle cell lymphoma cells cocultured with bone marrow stromal cells (BMSC) using small molecule inhibitors and RNAi based focal adhesion kinase silencing was performed. We could show that focal adhesion kinase is highly expressed in bone marrow infiltrates of mantle cell lymphoma and in mantle cell lymphoma cell lines. Stroma-mediated activation of focal adhesion kinase led to activation of multiple kinases (AKT, p42/44 and NF-κB), that are important for prosurvival and proliferation signalling. Interestingly, RNAi based focal adhesion kinase silencing or inhibition with small molecule inhibitors (FAKi) resulted in blockage of targeted cell invasion and induced apoptosis by inactivation of multiple signalling cascades, including the classical and alternative NF-κB pathway. In addition, the combined treatment of ibrutinib and FAKi was highly synergistic, and ibrutinib resistance of mantle cell lymphoma could be overcome. These data demonstrate that focal adhesion kinase is important for stroma-mediated survival and drug-resistance in mantle cell lymphoma, providing indications for a targeted therapeutic strategy
Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity
No full textA Corrigendum on
A TNFR2-specific TNF fusion protein with improved in vivo activity
by Vargas JG, Wagner J, Shaikh H, Lang I, Medler J, Anany M, Steinfatt T, Mosca JP, Haack S, Dahlhoff J, Büttner-Herold M, Graf C, Viera EA, Einsele H, Wajant H and Beilhack A (2022) Front. Immunol. 13:888274. doi: 10.3389/fimmu.2022.88827
Individual-based modeling and predictive simulation of fungal infection dynamics
No full textThe human-pathogenic fungus Aspergillus fumigatus causes life-threatening infections in immunocompromised patients and poses increasing challenges for the modern medicine. A. fumigatus is ubiquitously present and disseminates via small conidia over the air of the athmosphere. Each human inhales several hundreds to thousands of conidia every day. The small size of conidia allows them to pass into the alveoli of the lung, where primary infections with A. fumigatus are typically observed. In alveoli, the interaction between fungi and the innate immune system of the host takes place. This interaction is the core topic of this thesis and covered by mathematical modeling and computer simulations. Since in vivo laboratory studies of A. fumigatus infections under physiological conditions is hard to realize a modular software framework was developed and implemented, which allows for spatio-temporal agent-based modeling and simulation. A to-scale A. fumigatus infection model in a typical human alveolus was developed in order to simulate and analyze the infection scenario under physiological conditions. The process of conidial discovery by alveolar macrophages was modeled and simulated with different migration modes and different parameter configurations. It could be shown that chemotactic migration was required to find the pathogen before the onset of germination. A second model took advantage of evolutionary game theory on graphs. Here, the course of infection was modeled as a consecutive sequence of evolutionary games related to the complement system, alveolar macrophages and polymorphonuclear neutrophilic granulocytes. The results revealed a central immunoregulatory role of alveolar macrophages. In the case of high infectious doses it was found that the host required fully active phagocytes, but in particular a qualitative response of quantitatively sufficient polymorphonuclear neutrophilic granulocytes.Der human-pathogene Schimmelpilz Aspergillus fumigatus verursacht tödliche Infektionen und Erkrankungen vorrangig bei immunsupprimierten Patienten und stellt die moderne Medizin vor zunehmende Herausforderungen. A. fumigatus ist ubiquitär präsent und verbreitet sich über sehr kleine Konidien durch Luftströmungen in der Athmosphäre. Mehrere Hundert bis Tausende dieser Konidien werden täglich durch jeden Menschen eingeatmet. Die geringe Größe der infektiösen Konidien erlauben es dem Pilz bis in die Alveolen der Lunge des Wirtes vorzudringen,in denen eine Primärinfektionen mit A. fumigatus am häufigsten stattfindet. Die Alveolen sind der zentrale Schauplatz der Interaktion zwischen dem Pilz und dem angeborenen Immunsystem, welche Gegenstand dieser Arbeit ist. Diese Interaktion wird mit Hilfe von mathematischen Modellen und Computersimulationen nachgestellt und untersucht, da eine A. fumigatus Infektion im Nasslabor in vivo unter physiologischen Bedingungen nur sehr schwer realisiert werden kann. Als Grundlage für dieses Vorhaben wurde ein modulares Software-Paket entwickelt, welches agentenbasierte Modellierung und entsprechende Simulationen in Raum und Zeit ermöglicht. Ein maßstabsgetreues mathematisches Infektionsmodell in einer typischen menschlichen Alveole wurde entwickelt und die Suchstrategien von Alveolarmakrophagen unter der Berücksichtigung verschiedener Parameter wie Migrationsgeschwindigkeit, dem Vorhandensein von Chemokinen, dessen Diffusion und Chemotaxis untersucht. Es zeigte sich, dass Chemotaxis, notwendig ist, um die Konidie rechtzeitig finden zu können. In einem weiteren Modell, welches auf das Konzept evolutionärer Spieltheorie auf Graphen zurückgegriff, wurde der Infektionsverlauf als aufeinanderfolgende Serie evolutionärer Spiele mit dem Komplementsystem, Alveolarmakrophagen und Neutrophilen nachgestellt. Aus den Simulationsergebnissen konnte eine zentrale immunregulatorische Rolle von Alveolarmakrophagen entnommen werden
JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma
No full textCell adhesion in the multiple myeloma (MM) microenvironment is a mechanism by which MM plasma cells escape the effects of therapy and survive. To improve clinical strategies and overcome drug resistance, approaches directed to both MMPCs and bone marrow microenvironment are under investigation. Here, we examined the cell membrane protein Junctional adhesion molecule-A (JAM-A) as a clinical biomarker and novel therapeutic target for MM.
We evaluated JAM-A expression by real time PCR (RT-PCR), flow cytometry and immunofluorescence microscopy in 132 MM patients at different stages and various MM cell lines. Next, we measured the concentrations of soluble JAM-A from MM and healthy subjects sera by enzyme linked immune assay (ELISA). We investigated JAM-A functionally in vitro and in vivo by transient gene silencing (siRNA) and with blocking antibodies.
Patient-derived plasma cells (MMPCs) expressed increased JAM-A expression levels when compared to control PC from healthy individuals. Elevated JAM-A expression correlated with poor prognosis (Figure 1A,B). Furthermore, soluble JAM-A was significantly increased in MM patient sera when compared to healthy subjects. Additionally, MM cell lines showed high expression of both membrane and cytoplasmic JAM-A. Consequently, inhibition of JAM-A using specific siRNA treatment resulted in diminished tumorigenic potential, including decreased colony formation, chemotaxis and migration. Importantly, treatment of luciferase+RPMI-8226 MM bearing NSG with a JAM-A blocking monoclonal antibody reduced significantly MM progression and dissemination in vivo when compared to MM bearing mice that received an non-specific isotype control antibody (Figure 1C).
Conclusively, our data suggest that JAM-A can serve as a biomarker of malignancy in MM patients. Soluble plasma JAM-A could contribute to serum-based clinical stratification. Furthermore, therapeutic targeting of JAM-A appears attractive for clinical translation
Targeting regulatory T cells by addressing tumor necrosis factor and its receptors in allogeneic hematopoietic cell transplantation and cancer
No full textAn intricate network of molecular and cellular actors orchestrates the delicate balance between effector immune responses and immune tolerance. The pleiotropic cytokine tumor necrosis factor-alpha (TNF) proves as a pivotal protagonist promoting but also suppressing immune responses. These opposite actions are accomplished through specialist cell types responding to TNF via TNF receptors TNFR1 and TNFR2. Recent findings highlight the importance of TNFR2 as a key regulator of activated natural FoxP3+ regulatory T cells (Tregs) in inflammatory conditions, such as acute graft-vs.-host disease (GvHD) and the tumor microenvironment. Here we review recent advances in our understanding of TNFR2 signaling in T cells and discuss how these can reconcile seemingly conflicting observations when manipulating TNF and TNFRs. As TNFR2 emerges as a new and attractive target we furthermore pinpoint strategies and potential pitfalls for therapeutic targeting of TNFR2 for cancer treatment and immune tolerance after allogeneic hematopoietic cell transplantation
Junctional adhesion molecule-C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans
No full textDeregulation such as overexpression of adhesion molecules influences cancer progression and survival. Metastasis of malignant cells from their primary tumor site to distant organs is the most common reason for cancer-related deaths. Junctional adhesion molecule (JAM)-C, a member of the Ig-like JAM family, can homodimerize and aid cancer cell migration and metastasis. Here we show that this molecule is dynamically expressed on multiple myeloma (MM) cells in the marrow and co-localizes with blood vessels within the bone marrow of mice and humans. Additionally, JAM-C upregulation inversely correlates with the downregulation of the canonical plasma cell marker CD138 (syndecan-1), whose surface expression has recently been found to dynamically regulate a switch between MM growth in situ and MM dissemination. Moreover, targeting JAM-C in a syngeneic in vivo MM model ameliorates MM progression and improves outcome. Overall, our data demonstrate that JAM-C might serve not only as an additional novel diagnostic biomarker but also as a therapeutic target in MM disease
Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease
No full textThe paucity of regulatory T cells (Tregs) limits clinical translation to control aberrant immune reactions including graft-versus-host disease (GVHD). Recent studies showed that the agonistic antibody to DR3 (αDR3) expanded CD4(+)FoxP3(+) Tregs in vivo. We investigated whether treating donor mice with a single dose of αDR3 could alleviate acute GVHD in a MHC-mismatched bone marrow transplantation model. αDR3 induced selective proliferation of functional Tregs. CD4(+) T cells isolated from αDR3-treated mice contained higher numbers of Tregs and were less proliferative to allogeneic stimuli. In vivo GVHD studies confirmed that Tregs from αDR3-treated donors expanded robustly and higher frequencies of Tregs within donor CD4(+) T cells were maintained, resulting in improved survival. Conventional T cells derived from αDR3-treated donors showed reduced activation and proliferation. Serum levels of proinflammatory cytokines (IFNγ, IL-1β, and TNFα) and infiltration of donor T cells into GVHD target tissues (gastrointestinal tract and liver) were decreased. T cells from αDR3-treated donors retained graft-vs-tumor (GVT) effects. In conclusion, a single dose of αDR3 alleviates acute GVHD while preserving GVT effects by selectively expanding and maintaining donor Tregs. This novel strategy will facilitate the clinical application of Treg-based therapies
- …
